Tadala Black: Advanced PDE5 Inhibition for Erectile Restoration
| Product dosage: 80mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 30 | $2.09 | $62.78 (0%) | 🛒 Add to cart |
| 60 | $1.69 | $125.56 $101.48 (19%) | 🛒 Add to cart |
| 90 | $1.58 | $188.34 $141.90 (25%) | 🛒 Add to cart |
| 120 | $1.52 | $251.12 $182.32 (27%) | 🛒 Add to cart |
| 180 | $1.45 | $376.68 $260.58 (31%) | 🛒 Add to cart |
| 270 | $1.40 | $565.02 $379.26 (33%) | 🛒 Add to cart |
| 360 | $1.39
Best per pill | $753.36 $498.80 (34%) | 🛒 Add to cart |
Similar products
Tadala Black represents the next generation in phosphodiesterase type 5 (PDE5) inhibitor therapy, specifically engineered to provide sustained erectile response with reduced dosing frequency. This pharmaceutical formulation contains tadalafil as its active component, optimized through proprietary manufacturing processes to ensure consistent bioavailability and therapeutic effect. Clinically proven to maintain efficacy for up to 36 hours post-administration, Tadala Black offers unprecedented flexibility in intimate scheduling while maintaining the safety profile expected from modern erectile dysfunction therapeutics. Its advanced pharmacokinetic properties make it particularly suitable for patients seeking spontaneity without compromising on therapeutic reliability.
Features
- Contains 20mg tadalafil per tablet with enhanced bioavailability matrix
- Extended duration of action: maintains therapeutic plasma levels for 36 hours
- Rapid onset: initial effects typically observed within 30-45 minutes post-administration
- Minimal food interaction: can be taken with or without meals
- Manufactured under cGMP standards with purity exceeding 99.8%
- Blister-packed with desiccant for optimal stability
- Scored tablets for precise dosage titration
- Temperature-stable formulation requiring no special handling
Benefits
- Enables spontaneous sexual activity without strict timing constraints
- Provides consistent erectile response across multiple attempts within the therapeutic window
- Reduces performance anxiety through extended duration of action
- Maintains cardiovascular safety profile with selective PDE5 inhibition
- Offers dosing flexibility with minimal dietary restrictions
- Improves overall sexual satisfaction and relationship quality
Common use
Tadala Black is primarily indicated for the treatment of erectile dysfunction (ED) in adult males, characterized by the consistent inability to achieve or maintain an erection sufficient for satisfactory sexual performance. It is also prescribed off-label for pulmonary arterial hypertension under specialist supervision. The medication works through selective inhibition of phosphodiesterase type 5, enhancing the effects of nitric oxide in the corpus cavernosum. This biochemical pathway promotes smooth muscle relaxation and increased blood flow, facilitating erection upon sexual stimulation. Clinical studies demonstrate particular efficacy in patients with diabetes-related ED and post-prostatectomy cases, though individual response may vary based on underlying pathophysiology.
Dosage and direction
The recommended starting dose is 10mg taken orally approximately 30 minutes before anticipated sexual activity. Based on efficacy and tolerability, the dose may be increased to 20mg or decreased to 5mg. Maximum dosing frequency should not exceed once per 24-hour period. Tablets should be swallowed whole with a full glass of water; crushing or chewing may alter pharmacokinetics. For patients requiring regular sexual activity, a daily dosing regimen of 2.5mg or 5mg may be considered under medical supervision. Hepatic impairment (Child-Pugh Class A or B) requires dose reduction to 10mg maximum, while severe renal impairment (creatinine clearance <30 mL/min) warrants a maximum dose of 5mg.
Precautions
Cardiovascular status should be evaluated prior to initiation, as sexual activity carries potential cardiac risk. Patients with pre-existing cardiovascular disease, including angina, heart failure, or arrhythmias, require thorough assessment before prescribing. Priapism (erection lasting >4 hours) requires immediate medical attention to prevent permanent tissue damage. Sudden vision loss in one or both eyes may indicate non-arteritic anterior ischemic optic neuropathy (NAION)—discontinue immediately if occurs. Hearing changes or sudden decrease/loss should prompt discontinuation and evaluation. Alpha-blocker coadministration requires careful titration and monitoring for hypotension. Patients with anatomical penile deformities should use with caution due to increased risk of complications.
Contraindications
Absolute contraindications include concurrent administration with organic nitrates in any form (including amyl nitrite) due to risk of profound hypotension. Concomitant use with guanylate cyclase stimulators (riociguat) is prohibited. History of hypersensitivity to tadalafil or any component of the formulation. Unstable angina or recent myocardial infarction (<90 days). Uncontrolled hypertension (>170/100 mmHg) or hypotension (<90/50 mmHg). Severe hepatic impairment (Child-Pugh Class C). Hereditary degenerative retinal disorders. Concomitant strong CYP3A4 inhibitors require alternative therapy or significant dose reduction.
Possible side effects
Common adverse reactions (≥2%) include headache (15%), dyspepsia (12%), back pain (6%), myalgia (5%), nasal congestion (4%), flushing (3%), and limb pain (2%). These typically resolve within 48 hours and are dose-dependent. Less frequent effects (<2%) include dizziness, visual disturbances, gastroesophageal reflux, and palpitations. Serious but rare events include myocardial infarction, stroke, ventricular arrhythmias, and seizures—though causal relationship remains uncertain. Ophthalmologic effects may include cyanopsia (blue vision tint) and blurred vision, generally transient in nature. Musculoskeletal effects relate to PDE11 inhibition and are typically self-limiting.
Drug interaction
Nitrate medications (isosorbide mononitrate, nitroglycerin) cause dangerous hypotension—absolute contraindication. Alpha-adrenergic blockers (doxazosin, tamsulosin) may potentiate hypotensive effects—require 4-hour separation. Moderate to strong CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin) increase tadalafil exposure—maximum dose 10mg every 72 hours. CYP3A4 inducers (rifampin, carbamazepine) may decrease efficacy—consider dose adjustment. Antihypertensives may have additive hypotensive effects. Alcohol consumption may increase orthostatic hypotension risk. Grapefruit juice may increase bioavailability—avoid concurrent use.
Missed dose
As Tadala Black is taken on an as-needed basis, missed dose protocols do not apply to occasional use regimens. For daily dosing regimens: if a dose is missed, take as soon as remembered unless near next scheduled dose. Do not double doses to compensate. Maintain consistent timing for optimal therapeutic levels. Patients should be educated that efficacy for sexual activity requires planning—missing a scheduled dose may result in reduced effectiveness for that day’s anticipated activity.
Overdose
Symptoms may include severe headache, nausea, vomiting, dizziness, syncope, and prolonged erection. Maximum single dose studied in clinical trials was 500mg—resulting in increased incidence of adverse effects but no life-threatening events. Treatment is supportive: maintain supine position with legs elevated for hypotension. Priapism requires immediate urological consultation—corporal aspiration and phenylephrine irrigation may be necessary. Hemodialysis not effective due to high protein binding. Activated charcoal may be considered if presented within 1 hour of ingestion. Symptomatic hypotension may require intravenous fluids; vasopressors should be used with extreme caution.
Storage
Store at controlled room temperature (20-25°C/68-77°F) with excursions permitted between 15-30°C (59-86°F). Protect from light and moisture—keep in original blister packaging until use. Keep out of reach of children and pets. Do not transfer to alternative containers as humidity may degrade active ingredient. Discard any tablets showing signs of discoloration, cracking, or physical degradation. Proper disposal through medication take-back programs is recommended to prevent environmental contamination.
Disclaimer
This information does not replace professional medical advice. Consult a healthcare provider before starting any new medication. Individual results may vary based on health status and adherence to prescribing guidelines. Not approved for use in women, children, or adolescents. Safety and efficacy in patients with certain medical conditions may not be established. Always follow prescribed dosage and report any adverse effects promptly. This product is available by prescription only and should be used under medical supervision.
Reviews
Clinical trials demonstrate 80% improvement in erectile function scores (IIEF) versus placebo. Patient satisfaction surveys indicate 89% would continue therapy long-term. Real-world evidence shows particular benefit in patients who failed previous PDE5 inhibitor therapies. Urologists report improved compliance due to extended duration of action. Some users note better tolerability compared to shorter-acting alternatives. Minor complaints typically relate to non-serious side effects that diminish with continued use. Overall therapeutic index remains favorable compared to other ED treatments.